FITLIFE BRANDS, INC. (FTLF) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | (m) | |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 3.90M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $3.90M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | (m) | $3.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $10.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | $10.68M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | $11.54M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | $12.70M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $13.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | $12.06M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | $11.35M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | $10.26M | $1.34M | (m) | (m) | 7.65× | Reported |
| 2023-12-31 | (m) | (m) | (m) | $7.55M | $1.02M | (m) | (m) | 7.37× | Reported |
| 2023-09-30 | (m) | (m) | (m) | $6.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | $5.54M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | $4.78M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $5.70M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | $6.47M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | $6.36M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | $6.57M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $6.23M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $26.93M | (m) | $6.24M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $27.15M | $17.00K | $6.47M | $18.00K | (m) | 0.06% | 359.28× | Reported |
| 2021-03-31 | (m) | $21.75M | (m) | $4.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $21.74M | $29.00K | $4.20M | $15.00K | (m) | 0.13% | 280.27× | Reported |
| 2020-09-30 | (m) | $19.50M | (m) | $2.93M | $14.00K | (m) | (m) | 209.07× | Reported |
| 2020-06-30 | (m) | $17.89M | (m) | $2.14M | $26.00K | (m) | (m) | 82.42× | Reported |
| 2020-03-31 | (m) | $19.77M | (m) | $2.70M | $36.00K | (m) | (m) | 75.00× | Reported |
| 2019-12-31 | (m) | $19.50M | $118.00K | $2.58M | $47.00K | (m) | 0.61% | 54.91× | Reported |
| 2019-09-30 | (m) | $19.31M | (m) | $2.30M | $76.00K | (m) | (m) | 30.32× | Reported |
| 2019-06-30 | (m) | $18.58M | (m) | $1.83M | $101.00K | (m) | (m) | 18.14× | Reported |
| 2019-03-31 | (m) | $18.34M | (m) | $1.64M | $145.00K | (m) | (m) | 11.28× | Reported |
| 2018-12-31 | (m) | $17.08M | (m) | $653.00K | $133.00K | (m) | (m) | 4.91× | Reported |
| 2018-09-30 | (m) | (m) | (m) | $-6.79M | $132.13K | (m) | (m) | -51.37× | Reported |
| 2018-06-30 | (m) | (m) | (m) | $-7.68M | $121.13K | (m) | (m) | -63.38× | Reported |
| 2018-03-31 | (m) | $16.82M | (m) | $-8.43M | $88.94K | (m) | (m) | -94.74× | Reported |
| 2017-12-31 | (m) | $17.80M | (m) | $-8.95M | $112.13K | (m) | (m) | -79.84× | Reported |
| 2017-09-30 | (m) | (m) | (m) | $-2.61M | $-109.49K | (m) | (m) | (m) | Reported |
| 2017-06-30 | (m) | $19.65M | (m) | $-2.49M | $-110.31K | (m) | (m) | (m) | Reported |
| 2017-03-31 | (m) | $23.02M | (m) | $-751.98K | $-112.16K | (m) | (m) | (m) | Reported |
| 2016-12-31 | (m) | $25.31M | (m) | $472.26K | $-109.39K | (m) | (m) | (m) | Reported |
| 2016-09-30 | (m) | $24.41M | (m) | $-26.97K | $115.15K | (m) | (m) | -0.23× | Reported |
| 2016-06-30 | (m) | $25.34M | (m) | $774.73K | $106.48K | (m) | (m) | 7.28× | Reported |
| 2016-03-31 | (m) | $21.97M | (m) | $-156.10K | $99.19K | (m) | (m) | -1.57× | Reported |
| 2015-12-31 | (m) | $17.93M | (m) | $-1.09M | $90.41K | (m) | (m) | -12.05× | Reported |
| 2015-09-30 | (m) | $17.29M | (m) | $183.34K | $81.26K | (m) | (m) | 2.26× | Reported |
| 2015-06-30 | (m) | $16.51M | (m) | $380.46K | $85.80K | (m) | (m) | 4.43× | Reported |
| 2015-03-31 | (m) | $17.47M | (m) | $909.88K | $90.30K | (m) | (m) | 10.08× | Reported |
| 2014-12-31 | (m) | $19.96M | (m) | $1.85M | $94.67K | (m) | (m) | 19.56× | Reported |
| 2014-09-30 | (m) | $21.49M | (m) | $2.17M | $99.13K | (m) | (m) | 21.89× | Reported |
| 2014-06-30 | (m) | $20.89M | (m) | $2.01M | $82.26K | (m) | (m) | 24.47× | Reported |
| 2014-03-31 | (m) | $19.96M | (m) | $1.71M | $61.55K | (m) | (m) | 27.80× | Reported |
| 2013-12-31 | (m) | $19.68M | (m) | $1.39M | $40.91K | (m) | (m) | 33.92× | Reported |
| 2013-09-30 | (m) | $19.38M | (m) | $1.52M | $-17.88K | (m) | (m) | (m) | Reported |
| 2013-06-30 | (m) | $19.08M | (m) | $1.50M | $-19.68K | (m) | (m) | (m) | Reported |
| 2013-03-31 | (m) | $19.20M | (m) | $1.76M | $-19.00K | (m) | (m) | (m) | Reported |
| 2012-12-31 | (m) | $18.09M | (m) | $1.88M | $-18.40K | (m) | (m) | (m) | Reported |
| 2012-09-30 | (m) | $17.44M | (m) | $1.37M | $-19.82K | (m) | (m) | (m) | Reported |
| 2012-06-30 | (m) | $16.06M | (m) | $1.19M | $-22.40K | (m) | (m) | (m) | Reported |
| 2012-03-31 | (m) | $14.06M | (m) | $822.47K | $-26.38K | (m) | (m) | (m) | Reported |
| 2011-12-31 | (m) | $12.09M | (m) | $208.66K | $-30.86K | (m) | (m) | (m) | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $8.15M | (m) | $-3.10M | $-139.79K | (m) | (m) | (m) | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |